Two Sigma Advisers
ADCT icon

Two Sigma Advisers’s ADC Therapeutics ADCT Stock Holding History

Two Sigma Advisers’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-120,567
Closed -$426K – 35
2025
Q4 		$426K Buy
+120,567
New +$489K ﹤0.01% 1850
2025
Q1 		– Sell
-65,267
Closed -$130K – 2365
2024
Q4 		$130K Buy
65,267
+35,991
+123% +$94.2K ﹤0.01% 2188
2024
Q3 		$92.2K Sell
29,276
-6,800
-19% -$21.4K ﹤0.01% 2173
2024
Q2 		$114K Buy
+36,076
New +$143K ﹤0.01% 2305

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Advisers's ADCT Position: Q1 2026 in Review

Two Sigma Advisers sold out of ADC Therapeutics (ADCT) in Q1 2026, closing a stake of 120,567 shares — an estimated $426K sold.

Two Sigma Advisers first reported a position in ADCT in Q2 2024 and held it in 4 quarters. The position peaked at $426K in Q4 2025. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Two Sigma Advisers reported no remaining ADC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 120,567 ADC Therapeutics shares in Q1 2026, an estimated $426K.
  • Two Sigma Advisers first reported a position in ADC Therapeutics in Q2 2024 and held it in 4 quarters.
  • Two Sigma Advisers's ADC Therapeutics position peaked at $426K in Q4 2025.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.